Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized registration trial comparing the entinostat-KEYTRUDA combination to standard of care chemotherapy in patients with NSCLC whose tumors have progressed following treatment with a PD-1 antagonist and platinum-based chemotherapy.

Next Previous
Trial Profile

A randomized registration trial comparing the entinostat-KEYTRUDA combination to standard of care chemotherapy in patients with NSCLC whose tumors have progressed following treatment with a PD-1 antagonist and platinum-based chemotherapy.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Syndax Pharmaceuticals

Most Recent Events

  • 05 Nov 2018 New trial record
  • 25 Oct 2018 According to a Syndax Pharmaceuticals media release, data from this trial could lead to regulatory approval both in the U.S. and Europe.
  • 25 Oct 2018 According to a Syndax Pharmaceuticals media release, this trial is expected to begin in the first half of 2019 and top-line data are anticipated in the second half of 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top